ALX Oncology Holdings Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ALX Oncology Holdings Inc. on June 30, 2026, covering events that occurred on June 29, 2026. The filing addresses significant changes to the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignation: Corey Goodman, Ph.D., resigned as Chairman of the Board and as a member of the Board and all its committees, effective June 29, 2026.
- Reason for Departure: Dr. Goodman resigned for personal reasons and explicitly stated there was no disagreement with the Company regarding operations, policies, or practices.
- Appointment: Scott Garland, an independent director, was appointed as the new Chairman of the Board, effective June 29, 2026.
- Committee Restructuring: The Board approved new committee compositions:
- Audit Committee: Rekha Hemrajani (Chair), Daniel J. Curran, M.D., and Scott Garland.
- Compensation Committee: Chris Takimoto, M.D., Ph.D., F.A.C.P. (Chair), and Scott Garland.
- Corporate Governance and Nominating Committee: Daniel J. Curran, M.D. (Chair), and Rekha Hemrajani.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, operational outlook, or specific risk factors. A press release issued on June 30, 2026, is furnished as Exhibit 99.1 but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the effective date of Dr. Goodman's resignation and Dr. Garland's appointment (June 29, 2026).
- Confirm the new composition of the Audit, Compensation, and Corporate Governance committees.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the leadership transition not detailed in the 8-K text.
- Note that the resignation was for personal reasons with no reported disagreement on company matters.